β Home
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (465) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ§© Revenue Segmentation by Product
Switch to Location
| Fiscal year | Segment | Value |
|---|---|---|
| 2022 | Top 20 products | 32.14B |
| 2022 | Anti Infectives sold under Sandoz name | 777M |
| 2022 | Total anti-infectives net sales | 1.2B |
| 2022 | Rest of portfolio | 9.16B |
| 2021 | Top 20 products | 32.66B |
| 2021 | Anti Infectives sold under Sandoz name | 707M |
| 2021 | Total anti-infectives net sales | 1.1B |
| 2021 | Rest of portfolio | 9.33B |
| 2020 | Top 20 products | 29.92B |
π° Explore more revenue segmentation data for Novartis!
Sign up for free or log inπ Donβt miss "The Checklist Value Investor β A Smarter Way to Pick Stocks" β free!